DOCSLIB.ORG

Malta Medicines List 25 7 07

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Defined Daily Doses Pharmacological Dispensing Active Ingredients Trade Name Dosage strength Dosage form ATC Code Comments (WHO) Classification Class Glucobay 50 50mg Alpha Glucosidase Inhibitor - Blood Acarbose Tablet 300mg A10BF01 PoM Glucose Lowering Glucobay 100 100mg Medicine Carbonic Anhydrase Inhibitor - Acetazolamide Diamox 250mg Tablet 750mg S01EC01 PoM Antiglaucoma Preparation Parasympatho- Powder and solvent for solution for mimetic - Acetylcholine Chloride Miovisin® 10mg/ml Refer to PIL S01EB09 PoM eye irrigation Antiglaucoma Preparation Zovirax™ Suspension 200mg/5ml Oral suspension Medovir 200 200mg Tablet Virucid 200 Zovirax® 200mg Dispersible film-coated tablets 4gAntiviral J05AB01 PoM Zovirax® 800mg Aciclovir Aciclovir Medovir 800 800mg Tablet Virucid 800 Virucid 400 400mg Tablet Zovirax® Cream 5% w/w Cream Refer to PIL Antiviral D06BB03 PoM Medovir Zovirax® Eye Ointment 3% w/w Eye ointment Refer to PIL Antiviral S01AD03 PoM Neotigason® 10mg Retinoid - Acitretin Capsule 35mg D05BB02 PoM Neotigason® 25mg Antipsoriatic Acrivastine Benadryl® Allergy Relief 8mg Capsule 24mg Antihistamine R06AX18 OTC Antidiarrhoeal and Activated Charcoal Biocarbon® 0.25g Tablet 5g A07BA01 OTC Antiflatulent Dentinox® Infant Colic 42mg/ml Oral suspension Drops Antifoaming agent - Activated Dimethicone Aero-OM® 100mg/ml Oral drops emulsion Refer to PILPreparation for colic A02X OTC or wind pain Aero-OM® 40mg Tablet Activated dimeticone, Antacid and Asilone Antacid Tablets 270mg 500mg Tablet Refer to PIL A02AB10 OTC Dried aluminium hydroxide Antiflatulent Cream Retinoid - Antiacne Adapalene Differine® 0.1% w/w Refer to PIL D10AD03 PoM preparation Gel Cardiac Preparation Adenosine Adenocor® 3mg/ml Solution for injection 15mg for Supraventricular C01EB10 PoM Arrhythmias Bisphosphonate - Fosamax® Once Weekly Agent affecting Bone Alendronic Acid 70mg Tablet 10mg M05BA04 PoM 70mg Structure and Mineralization Alfacalcidol One-Alpha® 0.25mcg 0.25mcg Capsule soft 1mcg Vitamin D Analogue A11CC03 PoM Film-coated sustained release Alpha- Xatral® SR 5mg tablet Adrenoreceptor Antagonist - Alfuzosin Hydrochloride 7.5mg G04CA01 PoM Medicine used in Benign Prostatic Xatral® XL 10mg Prolonged release tablet Hypertrophy Alginic acid, 50mg Compound Alginate Sodium bicarbonate, 170mg Gaviscon Tablets Chewable tablets Refer to PIL Preparation - A02AX OTC Aluminium hydroxide, 100mg Antacid Preparation Magnesium trisilicate 25mg Allergan Extract of Grass Grazax® 75 000 SQ-T 75000 SQ-T Oral lyophilisate Refer to PIL Allergen Extract V01AA02 PoM Pollen from Timothy Allopurinol Zyloric® 100mg Cellidrin® 100mg Xanthine Oxidase Allopurinol Alopron 300 Tablet 400mgInhibitor - Antigout M04AA01 PoM Allopurinol Preparation 300mg Zyloric® Cellidrin® 300mg Zolaram 0.5 0.5g Zolaram 1 1mg Benzodiazepine Xanax® Tablets 250 Alprazolam 250mcg Tablet 1mg Derivative - N05BA12 PoM micrograms Anxiolytic Xanax® Tablets 500 500mcg micrograms Antihidrotic - Aluminium Chloride Preparation Driclor® 20% Solution for topical application Refer to PIL D11AA OTC Hexahydrate Suppressing Perspiration Aluminium hydroxide, 220mg/5ml Antacid and Magnesium hydroxide, Actonorm Gel 200mg/5ml Oral suspension Refer to PIL A02AX OTC Antiflatulent Activated dimethicone 25mg/5ml Aluminium oxide, 114mg/5ml Antacid and Magnesium hydroxide, Maalox® Plus® 200mg/5ml Oral suspension Refer to PIL A02AF01 OTC Antiflatulent Simethicone 25mg/5ml PK-Merz® 100mg Film-coated tablets 200mg Dopaminergic Agent Amantadine Sulphate - Medicine used in N04BB01 PoM PK-Merz® Infusion 200mg/500ml Solution for infusion Refer to PIL Parkinsonism Muciclar 75mg Modified release capsule hard PoM Ambrolitic® 30mg Capsule PoM Ambroxol Hydrochloride Mucolytic - Cough (Cyclohexanol Mucosolvan® 30mg Tablet 120mg R05CB06 Preparation Hydrochloride) PoM Mucosolvan® 5mg/mL Syrup Muciclar 3mg/ml OTC Aminoglycoside- Amikacin 500mg Uzix 500mg Solution for injection 1g J01GB06 PoM Antibiotic Potassium- Sparing Amiloride Hydrochloride Amiloride 5mg Tablet 10mg C03DB01 PoM Agent - Diuretic Potassium- Sparing Amiloride hydrochloride, 5mg Milorex Tablets Tablet Refer to PIL Agent + Thiazide - C03EA01 PoM Hydrochlorothiazide 50mg Diuretic Xanthine - Aminophylline Aminophylline 23.973mg/ml Solution for injection 600mg R03DA05 PoM Bronchodilator Cordarone® Scored tablet 200mg Amiodarone® Tablet Amiodarone Hydrochloride 200mg Antiarrhythmic C01BD01 PoM Cordarone® 150mg Solution for injection Solian® 200 100mg Benzamide - Amisulpride Tablet 400mg N05AL05 PoM Solian® 400 400mg Antipsychotic Amirol 10 Film-coated tablets 10mg Non-selective Tryptizol 10mg Tablets Monoamine Amitriptyline Hydrochloride 75mg N06AA09 PoM Reuptake Inhibitor - Antidepressant Amirol 25 Film-coated tablets 25mg Tryptizol 25mg Tablets Amlo Amlodipine 10mg Tablets 10mg LofralTM-10 Istin™ Dihydropyridine Amlodipine Tablet 5mg derivative - Calcium C08CA01 PoM Amlo Channel Blocker Amlodipine 5mg Tablets 5mg LofralTM-5 Istin™ Ammonium chloride, 100mg/5ml Sodium citrate, 50mg/5ml Menthol, 7.75mg/5ml Menthodex Cough Expectorant - Liquid extract of horehound, 0.0015ml/5ml Oral solution Refer to PIL R05X OTC Mixture Cough Preparation Tolu tincture, 0.001ml/5ml Squill tincture, 0.001ml/5ml Liquid extract of Tussilago 0.0004ml/5ml Augmentin®-Duo 400-57 400mg/5ml; Powder for oral suspension 57mg/5ml Noprilam DT 400 Noprilam DT 875mg Tablet Augmentin 875-125mg 125mg Film-coated tablets Tablets Augmentin 250-125mg Tablets Co-Amoxiclav Tablets 250mg BP 250-125mg 125mg Moxiclav® 375 Film-coated tablets 1g (Amoxicillin) Augmentin Duo 500- 125mg Tablets Broad-Spectrum Amoxicilin; 500mg Penicillin + Beta- 125mg J01CR02 PoM Clavulanic Acid Fungentin® Lactamase Inhibitor - Antibiotics Moxiclav® 625 500mg Noprilam Tablet 125mg Fungentin® 125mg/5ml Moxiclav® 156.25mg- 31.25mg/5ml 5ml Powder for oral suspension Fungentin® 250mg/5ml Moxiclav® Forte 62.5mg/5ml 312.5mg-5ml Augmentin® Intravenous 500mg 600mg 100mg Powder for solution for injection or 3g (Amoxicillin) infusion Augmentin® Intravenous 1000mg 1.2g 200mg Moxilen Amoxil® Capsules 500mg Capsule 500mg Flemoxin Solutab® 500 500mg Tablet Moxilen Amoxil® Capsules 250mg Capsule 250mg Amoxicillin Capsules Flemoxin Solutab® 250 250mg Tablet Broad-Spectrum Amoxicillin Flemoxin® Suspension 150mg/5ml 1g J01CA04 PoM Penicillin - Antibiotic Flemoxin® Drops 100mg/ml Moxilen Amoxil® Syrup Sucrose- Free Dye-Free 125mg/5ml Suspension 125mg per Powder for oral suspension 5ml Amoxil® Syrup Sucrose- Free Dye-Free Suspension 250mg per 5ml 250mg/5ml Flemoxin® Suspension Forte Amphotericin (Liposomal Polyene Antifungal AmBisone® for Injection 50mg Powder for solution for infusion 35mg J02AA01 PoM Amphotericin) Antifungal Concentrate for solution for Amsacrine Amsidine 50mg/ml Refer to PIL Antineoplastic Agent L01XX01 PoM infusion Amylmetacresol, Strepsils® Menthol & 0.6mg 1.2mg Antiseptics + 2,4-Dichlorobenzylalcohol, Lozenge Refer to PIL R02A OTC Eucalyptus 8mg Anaesthetic Levomenthol Amylmetacresol, Strepsils® with Vitamin 0.6mg 1.2mg 2,4-Dichlorobenzylalcohol, Lozenge Refer to PIL Antiseptics R02AA20 OTC C 100mg 100mg Vitamin C Strepsils® Original Amylmetacresol; 0.6mg Strepsils® Honey & Lozenge Refer to PILAntiseptics R02AA20 OTC 2.4-Dichlorobenzyl Alcohol Lemon 1.2mg Strepsils® Sugar Free Hormone Antagonist Anastrozole Arimidex® 1mg Coated tablets 1mg - Antineoplastic L02BG03 PoM Agent 1.36% w/v Dianeal PD1 Glucose 0.57% w/v 1.36%w-v 13.6mg-ml 0.39% w/v 0.0257% w/v 0.0152% w/v 2.27% w/v Dianeal PD1 Glucose 0.57% w/v 2.27%w-v 22.7mg-ml 0.39% w/v 0.0257% w/v 0.0152% w/v 3.86% w/v Dianeal PD1 Glucose 0.57% w/v Anhydrous glucose, 3.86%w-v 38.6 mg-ml 0.39% w/v 0.0257% Sodium chloride, w/v 0.0152% w/v Solution for Sodium lactate, Solution for peritoneal dialysis Refer to PIL B05DB PoM Peritoneal Dialysis Calcium chloride, 2.27% w/v 0.538% Magnesium chloride Dianeal PD4 Glucose w/v 0.448% w/v 2.27%w-v 22.7mg-ml 0.184%w/v 0.0051% w/v 1.36% w/v 0.538% Dianeal PD4 Glucose w/v 0.448% w/v 1.36%w-v 13.6mg-ml 0.184%w/v 0.0051% w/v 3.86% w/v 0.538% Dianeal PD4 Glucose w/v 0.448% w/v 3.86%w-v 38.6 mg-ml 0.184%w/v 0.0051% w/v Anhydrous lanolin, 1% w/w 14.5% White soft paraffin, E45 w/w 12.6% Cream Refer to PIL Emollient D02AC OTC Light liquid paraffin w/w Anhydrous Lidocaine 20mg Hydrochloride; Lignospan Special Solution for Injection Refer to PIL Local Anaesthetic N01BB52 PoM 12.5mcg Adrenaline Epinephrine Anhydrous Metoclopramide Metoclopramide Injection Propulsive - Anti- 10mg/2ml Solution for injection 30mg A03FA01 PoM Hydrochloride BP 10mg-2ml emetic Antihistamine + Antazoline hydrochloride, 0.5mg/ml Spersallerg® Eye drops solution Refer to PIL Degongestant - Anti- S01GA52 PoM Tetryzoline hydrochloride 0.4mg/ml allergic Preparation Antihistamine + Antazoline phosphate, 0.15mg/ml Allergopos® N Eye drops solution Refer to PIL Degongestant - Anti- S01GA52 OTC Tetryzoline hydrochloride 0.5mg/ml allergic Preparation Antithrombin III Baxter Antithrombin 50IU/ml Pdr & solv for soln for inj or inf 2.1TU Antithrombotic agent B01AB02 PoM 50 I.U. per ml Proteinase Inhibitor - Aprotinin Trasylol® 10000KIU/ml Solution for infusion 500TU B02AB01 PoM Antifibrinolytic Arachis oil, 57.3% 5.0% Treatment for Ear Chlorobutanol, Cerumol® Ear Drops Ear drops solution Refer to PIL S02DC OTC 2.0% wax removal p-Dichlorobenzene Posterior Pituitary Argipressin Pitressin™ Ampoules 20PU/ml Solution for injection Refer to PIL H01BA06 PoM Hormone Septanest with 40mg Adrenaline 1 per 100 10mcg Articaine hydrochloride; 000 Solution for Injection Refer to PILLocal Anaesthetic N01BB58 PoM Adrenaline
Recommended publications
  • Topical Budesonide for Treating Giant Rectal Pseudopolyposis

    Topical Budesonide for Treating Giant Rectal Pseudopolyposis

    ANTICANCER RESEARCH 25: 2961-2964 (2005) Topical Budesonide for Treating Giant Rectal Pseudopolyposis CHARALAMPOS PILICHOS1, ATHENA PREZA1, MARIA DEMONAKOU2, DIMITRIOS KAPATSORIS1 and CONSTANTINOS BOURAS1 1First Department of Internal Medicine and 2Department of Pathology, Sismanogleion Hospital, Athens, Greece Abstract. Pseudopolyps are a frequent finding in the course of Case Report inflammatory bowel disease. They are non-neoplastic lesions resulting from a regenerative and healing process that leaves A 45-year-old male patient was admitted to our service in July inflamed colonic mucosa in polypoid configuration. Data about 2002 for acute rectal bleeding. All laboratory tests were their management is lacking. "Giant" pseudopolyps can be normal, except an increase of aminotransferases level (>10 N) mistaken for adenocarcinomas and, as they rarely regress with and a serological profile consistent with acute hepatitis B or a medical management alone, a surgical resection is often required. flare of chronic hepatitis B (HbsAg +, HbsAb –, HbeAg –, A case of giant pseudopolyposis treated non-surgically, in a patient HbeAb +, HbcAb-IgM +). The patient underwent lower with concomitant ulcerative colitis and chronic hepatitis B, is gastro-intestinal endoscopy and multiple biopsies were taken reported, representing a co-morbidity complicating an eventual from a bulky rectal mass lesion (Figure 1). Histological study conservative treatment. The clinical implementation of topical revealed alterations compatible with inflammatory bowel budesonide was originally tested, resulting in clinical, endoscopic disease (IBD) with no dysplasia (Figure 2). Because of the and histological remission. Budesonide seems a promising therapy atypical macroscopic features and the high suspicion of rectal for IBD, particularly when a comorbidity with viral hepatitis exist.
  • Practice Parameters for the Surgical Treatment of Ulcerative Colitis Howard Ross, M.D

    Practice Parameters for the Surgical Treatment of Ulcerative Colitis Howard Ross, M.D

    PRACTICE PARAMETERS Practice Parameters for the Surgical Treatment of Ulcerative Colitis Howard Ross, M.D. • Scott R. Steele, M.D. • Mika Varma, M.D. • Sharon Dykes, M.D. Robert Cima, M.D. • W. Donald Buie, M.D. • Janice Rafferty, M.D. Prepared by the Standards Practice Task Force of the American Society of Colon and Rectal Surgeons he American Society of Colon and Rectal Surgeons the most common surgical indication for UC. Whether is dedicated to assuring high-quality patient care it is secondary to an inability to control symptoms, poor Tby advancing the science, prevention, and manage- quality of life, risks/side effects of chronic medical therapy ment of disorders and diseases of the colon, rectum, and (especially long-term corticosteroids), noncompliance, or anus. The Standards Committee is composed of Society growth failure, patients may opt for surgery in the elective members who are chosen because they have demonstrat- or semielective setting.3 Complete removal of all the poten- ed expertise in the specialty of colon and rectal surgery. tial disease-bearing tissue is theoretically curative in UC. This Committee was created to lead international efforts Operative options include an abdominal colectomy or total in defining quality care for conditions related to the co- proctocolectomy with either a permanent end ileostomy or lon, rectum, and anus. This is accompanied by develop- surgical construction of a “new” rectum through an IPAA ing Clinical Practice Guidelines based on the best available that restores GI continuity.4,5 All these procedures may evidence. These guidelines are inclusive, and not prescrip- be performed by using open or minimally invasive tech- tive.
  • Glucose-Uptake Activity and Cytotoxicity of Diterpenes and Triterpenes Isolated from Lamiaceae Plant Species

    Glucose-Uptake Activity and Cytotoxicity of Diterpenes and Triterpenes Isolated from Lamiaceae Plant Species

    molecules Article Glucose-Uptake Activity and Cytotoxicity of Diterpenes and Triterpenes Isolated from Lamiaceae Plant Species Ninon G. E. R. Etsassala 1 , Kadidiatou O. Ndjoubi 2 , Thilly J. Mbira 2, Brendon Pearce 3 , Keenau Pearce 3, Emmanuel I. Iwuoha 4 , Ahmed A. Hussein 2 and Mongi Benjeddou 3,* 1 Department of Horticultural Sciences, Cape Peninsula University of Technology, Symphony Rd., Bellville 7535, South Africa; [email protected] 2 Chemistry Department, Cape Peninsula University of Technology, Symphony Rd., Bellville 7535, South Africa; [email protected] (K.O.N.); [email protected] (T.J.M.); [email protected] (A.A.H.) 3 Precision Medicine Laboratory, Department of Biotechnology, 2nd Floor, Life Science Building, University of the Western Cape, Cape Town 7530, South Africa; brendon.biff@gmail.com (B.P.); [email protected] (K.P.) 4 Chemistry Department, University of the Western Cape, Private Bag X17, Bellville 7535, South Africa; [email protected] * Correspondence: [email protected]; Tel.: +27-21-959-2080; Fax: +27-21-959-3505 Academic Editors: Patrícia Rijo, Vera Isca and Daniele Passarella Received: 17 July 2020; Accepted: 14 August 2020; Published: 10 September 2020 Abstract: The prevalence of diabetes mellitus (DM), considered one of the most common metabolic disorders, has dramatically increased and resulted in higher rates of morbidity and mortality around the world in the past decade. It is well known that insulin resistance in target tissues and a deficiency in insulin secretion from pancreatic β-cells are the main characteristics of type 2 diabetes. The aim of this study was the bio-evaluation of compounds isolated from three selected plant species: namely, Salvia africana-lutea, Leonotis ocymifolia, and Plectranthus madagascariensis, for their glucose-uptake ability.
  • Redalyc.Changes, Functional Disorders, and Diseases in the Gastrointestinal Tract of Elderly

    Redalyc.Changes, Functional Disorders, and Diseases in the Gastrointestinal Tract of Elderly

    Nutrición Hospitalaria ISSN: 0212-1611 info@nutriciónhospitalaria.com Grupo Aula Médica España Grassi, M.; Petraccia, L.; Mennuni, G.; Fontana, M.; Scarno, A.; Sabetta, S.; Fraioli, A. Changes, functional disorders, and diseases in the gastrointestinal tract of elderly Nutrición Hospitalaria, vol. 26, núm. 4, julio-agosto, 2011, pp. 659-668 Grupo Aula Médica Madrid, España Available in: http://www.redalyc.org/articulo.oa?id=309226773001 How to cite Complete issue Scientific Information System More information about this article Network of Scientific Journals from Latin America, the Caribbean, Spain and Portugal Journal's homepage in redalyc.org Non-profit academic project, developed under the open access initiative Nutr Hosp. 2011;26(4):659-668 ISSN 0212-1611 • CODEN NUHOEQ S.V.R. 318 Revisión Changes, functional disorders, and diseases in the gastrointestinal tract of elderly M. Grassi1, L. Petraccia1, G. Mennuni1, M. Fontana2, A. Scarno1, S. Sabetta1 and A. Fraioli1 1Deparment Internal Medicine and Medical Disciplines. Unit of Internal Medicine E, Medical Therapy and Thermal Medicine - School of Specialization in Thermal Medicine. 2Department of Biochemical Sciences. Sapienza University of Rome. Rome. Italy. Abstract CAMBIOS, DOLENCIAS FUNCIONALES Y ENFERMEDADES EN EL SISTEMA This article describes changes in the basic digestive GASTROINTESTINAL EN PERSONAS MAYORES functions (motility, secretion, intraluminal digestion, absorption) that occur during aging. Elderly individuals frequently have oropharyngeal muscle dysmotility and Resumen altered swallowing of food. Reductions in esophageal Este artículo describe los cambios en las funciones peristalsis and lower esophageal sphincter (LES) pres- digestivas básicas (motilidad, secreción, digestión intralu- sures are also more common in the aged and may cause minal, absorción) que ocurren en el envejecimiento.
  • Automated Detection of Adverse Drug Events by Data Mining of Electronic Health Records Emmanuel Chazard

    Automated Detection of Adverse Drug Events by Data Mining of Electronic Health Records Emmanuel Chazard

    Automated detection of adverse drug events by data mining of electronic health records Emmanuel Chazard To cite this version: Emmanuel Chazard. Automated detection of adverse drug events by data mining of electronic health records. Human health and pathology. Université du Droit et de la Santé - Lille II, 2011. English. NNT : 2011LIL2S009. tel-00637254 HAL Id: tel-00637254 https://tel.archives-ouvertes.fr/tel-00637254 Submitted on 31 Oct 2011 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. UNIVERSITE LILLE NORD DE FRANCE ÉCOLE DOCTORALE BIOLOGIE SANTE FACULTE DE MEDECINE HENRY WAREMBOURG THESE SCIENTIFIQUE POUR L ’OBTENTION DU GRADE DE DOCTEUR DE L ’U NIVERSITE DE LILLE 2 BIOSTATISTIQUES Soutenue le 09/02/2011 par Emmanuel Chazard AUTOMATED DETECTION OF ADVERSE DRUG EVENTS BY DATA MINING OF ELECTRONIC HEALTH RECORDS Jury : Pr. Elske Ammenwerth Examinateur Pr. Régis Beuscart Examinateur Pr. Paul Landais Rapporteur Pr. Nicos Maglaveras Rapporteur Pr. Christian Nøhr Examinateur Pr. Cristian Preda Examinateur Pr. Alain Venot Examinateur Automated detection of Adverse Drug Events by Data Mining of Electronic Health Records Emmanuel Chazard, PhD Thesis Page 2 of 262 SUMMARY Automated Detection of Adverse Drug Events by Data Mining of Electronic Health Records Introduction Adverse Drug Events (ADE) are injuries due to medication management rather than the underlying condition of the patient.
  • 8-GI Drugs Final

    8-GI Drugs Final

    Gastrointestinal Drugs Subcommittee: Prozialeck, Walter (Chair) [email protected] Escher, Emanuel [email protected] Garrison, James C. [email protected] Henry, Matthew, [email protected] Weber, Donna R [email protected] Recommended Curriculum Equivalent: 1.5 h Acid Reducers and Drugs for the Treatment of Peptic Ulcer Disease Proton pump inhibitors First generation Second generation OMEPRAZOLE ESOMEPRAZOLE LANSOPRAZOLE PANTOPRAZOLE RABEPRAZOLE Learning Objectives Physiology and pathophysiology Describe the synthesis and mechanism of H+ secretion by the parietal cells Mechanism of action Describe the mechanism of action of proton pump inhibitors and why they are selective for the parietal cell proton pump. Actions on organ systems Describe the pharmacological effects of the drugs on gastric function. Are there effects on other organ systems? Pharmacokinetics Describe the pharmacokinetics of proton pump inhibitors? Are there significant differences among the different drugs in this class? Adverse effects, drug interactions and contraindications Describe the principal adverse effects of proton pump inhibitors. Describe the clinically important drug interactions of proton pump inhibitors. Describe the principal contraindications of proton pump inhibitors. Therapeutic uses Describe the current therapeutic uses of proton pump inhibitors. 1 Clinical Pharmacology Omeprazole is perceived to be the most potent of this drug class in inhibiting CYP2C19 activity and is proposed to have potential drug interactions with other drugs metabolized by this P450 isoform. Concern has been raised about potential inhibition of clopidogrel activation in patients taking both drugs concurrently. Current consensus is that in such patients clopidogrel with pantoprazole may be a safer choice to reduce the probability of a drug interaction involving CYP2C19.
  • As Potential Targets Against SARS-Cov-2 Viral Proteins

    As Potential Targets Against SARS-Cov-2 Viral Proteins

    ew Vol 5 | Issue 1 | Pages 214-223 Journal of Clinical Anesthesia and Pain Management ISSN: 2578-658X Original Article DOI: 10.36959/377/356 In Silico Identification of Apigenin and Narcissin (Food- Flavonoids) as Potential Targets Against SARS-CoV-2 Viral Proteins: Comparison with the Effect of Remdesivir Vincent Brice Ayissi Owona1*, Borris RT Galani2 and Paul Fewou Moundipa1 1Laboratory of Molecular Pharmacology and Toxicology, Department of Biochemistry, Faculty of Science, Check for updates University of Yaounde 1, Yaounde, Cameroon 2Laboratory of Applied Biochemistry, Department of Biological Sciences, Faculty of Science, University of Ngaoundere, Ngaoundere, Cameroon Abstract Background: In this study, we demonstrate the potential role of Narcissin and apigenin, two natural flavonoids found in fruits and foods, as candidate compounds in the treatment against the novel corona virus infection using in silico tools. Methods: We have used computational molecular docking screening (Molegro Virtual Docker) to study the effect of selected flavonoids on main viral proteins including MERS-COV spike-RBD, RNA-polymerase, viral main protease, and papain-like protease. A grid resolution of 30 A° was used, together with an MM2 force field for energy minimization. Moreover, the MolDock Score and ReRank score were used as scoring functions. The results obtained were compared to those of Remdesivir, a drug under investigation for Covid-19 treatment. Results: Narcissin, Apigenin and Remdesivir were identified as strong inhibitors of Covid-19 proteins with MolDock scores of: MERS-COV Spike-RBD, PDB: 4KRO (-101.704, -61.069, -15.96), Papain-like protease MERS, PDB: 4P16 (-91.462, -47.314, -43.64), SARS-COV-2 main protease in complex with inhibitor UAW246, PDB: 6XBG (-151.124, -98.20, -150.12) respectively for the three drugs.
  • Malta Medicines List April 08

    Malta Medicines List April 08

    Defined Daily Doses Pharmacological Dispensing Active Ingredients Trade Name Dosage strength Dosage form ATC Code Comments (WHO) Classification Class Glucobay 50 50mg Alpha Glucosidase Inhibitor - Blood Acarbose Tablet 300mg A10BF01 PoM Glucose Lowering Glucobay 100 100mg Medicine Rantudil® Forte 60mg Capsule hard Anti-inflammatory and Acemetacine 0.12g anti rheumatic, non M01AB11 PoM steroidal Rantudil® Retard 90mg Slow release capsule Carbonic Anhydrase Inhibitor - Acetazolamide Diamox 250mg Tablet 750mg S01EC01 PoM Antiglaucoma Preparation Parasympatho- Powder and solvent for solution for mimetic - Acetylcholine Chloride Miovisin® 10mg/ml Refer to PIL S01EB09 PoM eye irrigation Antiglaucoma Preparation Acetylcysteine 200mg/ml Concentrate for solution for Acetylcysteine 200mg/ml Refer to PIL Antidote PoM Injection injection V03AB23 Zovirax™ Suspension 200mg/5ml Oral suspension Aciclovir Medovir 200 200mg Tablet Virucid 200 Zovirax® 200mg Dispersible film-coated tablets 4g Antiviral J05AB01 PoM Zovirax® 800mg Aciclovir Medovir 800 800mg Tablet Aciclovir Virucid 800 Virucid 400 400mg Tablet Aciclovir Merck 250mg Powder for solution for inj Immunovir® Zovirax® Cream PoM PoM Numark Cold Sore Cream 5% w/w (5g/100g)Cream Refer to PIL Antiviral D06BB03 Vitasorb Cold Sore OTC Cream Medovir PoM Neotigason® 10mg Acitretin Capsule 35mg Retinoid - Antipsoriatic D05BB02 PoM Neotigason® 25mg Acrivastine Benadryl® Allergy Relief 8mg Capsule 24mg Antihistamine R06AX18 OTC Carbomix 81.3%w/w Granules for oral suspension Antidiarrhoeal and Activated Charcoal
  • Review Article

    Review Article

    Review Article WIENER KLINISCHE WOCHENSCHRIFT The Middle European Journal of Medicine Wien Klin Wochenschr (2008) 120/1–2: –17 DOI 10.1007/s00508-007-0920-2 Printed in Austria Gastrointestinal motility in acute illness Sonja Fruhwald, Peter Holzer, and Helfried Metzler Department of Anesthesiology and Intensive Care Medicine, Medical University of Graz, Graz, Austria Received August 29, 2007, accepted after revision December 19, 2007 © Springer-Verlag 2008 Einfluss akuter Erkrankungen auf die Darmmotilität intake, and an interdigestive motility pattern starting se- Zusammenfassung. Kritisch kranke Patienten lei- veral hours after a meal. Undisturbed intestinal motility den häufig unter Störungen der Darmmotilität, einerseits depends critically on a balanced interaction between in- als Folge der primären Erkrankung, welche die Aufnahme hibition and excitation, and a disturbance in this balance auf eine Intensivstation notwendig macht, andererseits leads to severe derangements of intestinal motility. The- als Komplikation des Intensivaufenthaltes. Störungen der se motility disturbances differ in clinical appearance and Darmmotilität können durch Beeinträchtigungen der mus- location but can affect all parts of the gastrointestinal kulären Funktion des Gastrointestinaltraktes, der Schritt- tract. This review focuses on select motility disturbances macherzellen des Darmes oder der nervalen Aktivität such as gastroparesis, postoperative ileus, and Ogilvie’s ausgelöst werden. Das enterale Nervensystem als neu- syndrome. Generally effective methods
  • Product Monograph

    Product Monograph

    PRODUCT MONOGRAPH Sitcom LD Cream Each g contains : Euphorbia Prostrata Extract 1.0% w/w 10 mg (containing 0.315–0.825 mg total flavonoids calculated as apigenin-7-glucoside and 1.26–4.4 mg total phenolics calculated as gallic acid) and Lidocaine 3 % w/w 30 mg cream base. Cream Treatment of Haemorrhoids Manufactured By: Date of Preparation: The Madras Pharmaceuticals (05/07/2019) Old Mahabalipuram Road Karapakkam, Chennai Marketed By: Panacea Biotec Ltd. New Delhi 1 PART I: HEALTH PROFESSIONAL Page No. INFORMATION SUMMARY PRODUCT INFORMATION 4 INDICATIONS AND CLINICAL USE 4 CONTRAINDICATIONS 5 WARNINGS AND PRECAUTIONS 5 ADVERSE REACTIONS 7 DRUG INTERACTIONS 8 DOSAGE AND ADMINISTRATION 8 OVERDOSAGE 9 ACTION AND CLINICAL PHARMACOLOGY 9 STORAGE AND STABILITY 9 DOSAGE FORMS, COMPOSITION AND PACKAGING 9 PART II: SCIENTIFIC INFORMATION PHARMACEUTICAL INFORMATION 10 PART III: PATIENT INFORMATION 11 2 Sitcom LD Cream Each g contains : Euphorbia Prostrata Extract 1.0% w/w 10 mg (containing 0.315–0.825 mg total flavonoids calculated as apigenin-7-glucoside and 1.26–4.4 mg total phenolics calculated as gallic acid) and Lidocaine 3 % w/w 30 mg cream base. Cream Treatment of Haemorrhoids 3 PART I: HEALTH PROFESSIONAL INFORMATION SUMMARY PRODUCT INFORMATION Route of Dosage Form / Approved Indications Administration Strength Topical Sitcom LD Cream Euphorbia Prostrata is Euphorbia Prostrata indicated for: Extract 1.0% w/w 10 mg (containing 0.315–0.825 - Treatment of Bleeding mg total flavonoids Haemorrhoids calculated as apigenin- - In post- 7-glucoside and 1.26–4.4 haemorrhoidectomy. mg total phenolics calculated as gallic acid) and Lidocaine 3 % w/w 30 mg cream base.
  • Appendix 1 – Protocol for Preventing Or Reversing Chronic Disease The

    Appendix 1 – Protocol for Preventing Or Reversing Chronic Disease The

    Appendix 1 – Protocol for Preventing or Reversing Chronic Disease The first author has developed a protocol over the past decade for preventing or reversing chronic disease based on the following systemic medical principle: “at the present time, removal of cause is a necessary, but not necessarily sufficient, condition for restorative treatment to be effective”[1]. The protocol methodology refines the age-old principles of both reducing harm in addition to providing treatment, and allows better identification of factors that contribute to the disease process (so that they may be eliminated if possible). These contributing factors are expansive and may include a combination of Lifestyle choices (diet, exercise, smoking), iatrogenic and biotoxin exposures, environmental/occupational exposures, and psychosocial stressors. This strategy exploits the existing literature to identify patterns of biologic response using biomarkers from various modalities of diagnostic testing to capture a much broader list of potential contributing factors. Existing inflammatory bowel diseases (IBD) Biomarker Identification to Remove Contributing Factors and Implement Treatment The initial protocol steps are diagnostic. The main output of these diagnostics will be identification of the biomarker levels and symptoms that reflect abnormalities, and the directions of change required to eliminate these abnormalities. In the present study, hundreds of general and specific biomarkers and symptoms were identified from the core IBD literature. The highest frequency (based on numbers of record appearances) biomarkers and symptoms were extracted, and are listed in Table 1 (highest frequency items first, reading down each column before proceeding to the next column). They are not necessarily consensus biomarkers. They are biomarkers whose values were altered by a treatment or contributing factor, and reported in the core IBD literature.
  • Estonian Statistics on Medicines 2016 1/41

    Estonian Statistics on Medicines 2016 1/41

    Estonian Statistics on Medicines 2016 ATC code ATC group / Active substance (rout of admin.) Quantity sold Unit DDD Unit DDD/1000/ day A ALIMENTARY TRACT AND METABOLISM 167,8985 A01 STOMATOLOGICAL PREPARATIONS 0,0738 A01A STOMATOLOGICAL PREPARATIONS 0,0738 A01AB Antiinfectives and antiseptics for local oral treatment 0,0738 A01AB09 Miconazole (O) 7088 g 0,2 g 0,0738 A01AB12 Hexetidine (O) 1951200 ml A01AB81 Neomycin+ Benzocaine (dental) 30200 pieces A01AB82 Demeclocycline+ Triamcinolone (dental) 680 g A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+ Thymol (dental) 3094 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+ Cetylpyridinium chloride (gingival) 227150 g A01AD81 Lidocaine+ Cetrimide (O) 30900 g A01AD82 Choline salicylate (O) 864720 pieces A01AD83 Lidocaine+ Chamomille extract (O) 370080 g A01AD90 Lidocaine+ Paraformaldehyde (dental) 405 g A02 DRUGS FOR ACID RELATED DISORDERS 47,1312 A02A ANTACIDS 1,0133 Combinations and complexes of aluminium, calcium and A02AD 1,0133 magnesium compounds A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 811120 pieces 10 pieces 0,1689 A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 3101974 ml 50 ml 0,1292 A02AD83 Calcium carbonate+ Magnesium carbonate (O) 3434232 pieces 10 pieces 0,7152 DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 46,1179 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 2,3855 A02BA02 Ranitidine (O) 340327,5 g 0,3 g 2,3624 A02BA02 Ranitidine (P) 3318,25 g 0,3 g 0,0230 A02BC Proton pump inhibitors 43,7324 A02BC01 Omeprazole